Healthcare Review: Terra Tech, ZS Pharma, Amedisys, Insys Therapeutics, TherapeuticsMD Print
By Staff and Wire Reports   
Tuesday, 08 July 2014 13:39
In a letter to the SEC, Terra Tech ($TRTC) asks to withdraw its S-3 filed on April 17, 2014 stating that it has decided not to pursue it. The USPTO issues Notices of Allowance to ZS Pharma ($ZSPH) for two patent applications related to ZS-9 (sodium zirconium cyclosilicate), the firm's product candidate in Phase 3 for the treatment of hyperkalemia. Patent application 13/371,080 describes compositions of matter that include ZS-9 and patent application 14/036,489 covers methods of treating hyperkalemia with compositions described in '080. The patents, when issued, will be valid until 2032.

Amedisys ($AMED) reports that the SEC advised the company that it had completed its investigation into the firm's operations and participation in the Medicare program and does not intend to pursue any enforcement action.

Insys Therapeutics ($INSY) plans to file an NDA this quarter for Dronabinol Oral Solution for the treatment of chemotherapy-induced nausea and vomiting and for the treatment of anorexia in patients with AIDS.

Shares of TherapeuticsMD ($TXMD) are up 30% on robust volume in apparent response to FBR Capital's Outperform rating and $34 PT, representing almost a seven-fold increase from the current price. The company focuses on women's health, specifically hormone replacement therapies. Its four lead products in development are TX 12-001HR (estradiol + progesterone) for hormone replacement and to treat the symptoms of menopause; TX 12-002HR (progesterone) for the treatment of amenorrhea; TX 12-003HR (estradiol) for the treatment of moderate-to-severe vasomotor symptoms due to menopause and TX 12-004HR (estradiol) for the treatment of vulvar and vaginal atrophy in postmenopausal women.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus